Cyclacel Pharma (CYCC) Tops Q3 EPS by 4c

Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Cematrix wins $8.8M in new contracts, bringing YTD total to $43.2M
• Super Micro Computer rises on AI server market optimism